NCT01484080已完成1 期
Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Centro Nacional de Investigaciones Oncologicas CARLOS III3 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 3
- 主要终点
- Pathologic complete response
研究概览
简要总结
The investigators plan to study the efficacy of the combination of weekly paclitaxel + BIBF 1120 in early breast cancer using a neoadjuvant schedule and a randomized phase-II trial design, comparing the efficacy vs. weekly paclitaxel alone, followed by surgery and subsequent standards of care (anthracycline based chemotherapy, radiation or hormonal blockade).
详细描述
This is an open-label, multicenter, Phase I dose-escalation study to assess the safety and tolerability of oral (PO) BIBF 1120 administered with intravenous (IV) paclitaxel (80 mg/m2 on days 1, 8 and 15 every 3 weeks) to patients with breast cancer (see Figure 1 for the study flow chart). BIBF 1120 will be administered twice daily PO for 21 consecutive days (Days 1 to 21) in 3-week cycles (morning dose is skipped on the paclitaxel administration days)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Patients ≥18 year-old
- •Histological diagnosis of localized breast cancer with primary tumour over 2 cm on its longest diameter (measured by mammography and MRI). Any nodal status is allowed when it is an operable tumour at diagnosis. Multicentricity is allowed.
- •HER 2 negative (Inmunohistochemistry - or + over +++; FISH CISH (-); equivalent to HER2/CEP17 copies under 2: HER2 result ++/+++ needs FISH/CISH confirmation.
- •Measurable disease with a primary lesion >2 cm. by RECIST v1.1 criteria
- •Adequate hematologic, renal and hepatic function, defined by the following laboratory results obtained within 14 days prior to randomization/registration:
- •Absolute granulocyte count >1.5 x 109/L
- •Absolute platelet count >100 x 109/L
- •Hemogobin >10 g/dL
- •Serum creatinine >1.5 x UNL or a calculated creatinine clearance >50 ml/min
- •Serum bilirubin <1.25 UNL
- •AST/ALT <1.5 times UL
- •Premenopausal women must be under effective birth control (non-hormone) and continue its use for the duration of the study and even 6 months later.
- •For female with childbearing potential, a negative pregnancy test within the prior 7 days to the study enrolment
- •Life expectancy >6 months
排除标准
- •Metastatic or non-surgical breast cancer (including inflammatory).
- •Locally breast cancer with primary lesion under 2 cm. In case of multicentricity, it will not be admitted in the study unless any lesion would be over this length.
- •Previous or concurrent treatment of any kind for breast cancer: hormonal agents, conventional cytotoxic drugs, radiation therapy, targeted drugs, bisphosphonates, monoclonal antibodies or surgery. Chemoprevention with tamoxifen or raloxifene is allowed as far as the treatment was interrupted upon diagnosis and at least 4 weeks prior to inclusion. Same criteria for post-menopausal hormonal replacement therapy. Hormonal contraceptives should be discontinued.
- •HER-2 positive breast cancer defined as over-expression in Immunochemistry of HER-2 3+ or 2+ with positive FISH/CISH
- •Male patients.
- •Pregnancy, lactation or breastfeeding.
- •Active malignancy at any other side (including contra-lateral synchronous breast cancer) besides non-melanoma skin cancer or ductal/lobular of the breast or cervix in situ carcinoma, colon in situ carcinoma accurately treated as well as any other tumour diagnosis >5 years prior to registration without any sign of progression at present time.
- •Concurrent serious medical conditions such as myocardial infarction within 6 months prior to entry, congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension (under NYHA criteria), uncontrolled psychotic disorders, serious active infections, active peptic ulcer disease, psychiatric illness, HIV infection, active hepatitis, COPD or any other medical conditions that might be aggravated by treatment or limit compliance.
- •Inability to take oral medication
- •History of malabsorption syndrome
- •Proven allergy to paclitaxel or BIBF
- •Grade ≥2 peripheral neuropathy.
- •Major surgery within 4 weeks of registration (breast cancer surgery regardless of timing is an exclusion criteria).
- •Inability to comply with the study and follow-up procedures.
- •Anticoagulation therapy (except low-dose heparin and / or wash out with heparin as needed to maintain a permanent intravenous device) or antiplatelet therapy (except for treatment with low doses of aspirin <325 mg per day.
- •History of hemorrhagic or thromboembolic event clinically significant in the last 6 months.
- •Known hereditary predisposition to bleeding or thrombosis
研究组 & 干预措施
Arm I: BIBF1120+Paclitaxel
Experimental
2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
干预措施: BIBF + Paclitaxel (Drug)
Arm II: Paclitaxel
Active Comparator
Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Pathologic complete response
时间窗: Within 30 days after surgery
Pathologic complete response defined as the absence of tumor cells assessed on the surgical specimen + residual Ductal Carcinoma In Situ (DCIS) in the breast.
次要结局
- Determine predicting factors at the phosphoproteomic signature and its correlation with response to BIBF-1120(Baseline and end of priming phase.)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast CancerBreast CancerNCT00919880Tao OUYANG148
已完成
3 期
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian CancerOvarian NeoplasmsPeritoneal NeoplasmsNCT01015118Boehringer Ingelheim1,366
已完成
1 期
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLCSTAGE IIIA/B NSCLC / INOPERABLE LUNG CANCERNCT01757288University of Texas Southwestern Medical Center98
Unknown
2 期
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic CancerLocally Advanced Pancreatic CancerNCT03815461Chinese Academy of Medical Sciences60
Unknown
2 期
Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric CancerGastric CancerNCT04258657Beijing Friendship Hospital20